XML 54 R40.htm IDEA: XBRL DOCUMENT
v3.20.4

License, Collaborative and Employment Agreements and Commitments - Additional Information (Details) - USD ($) |  |  |  |  |  |  |  |  | 1 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Dec. 30, 2020 | Aug. 07, 2019 | Sep. 05, 2018 | Sep. 05, 2018 | Aug. 31, 2015 | Aug. 29, 2015 | Aug. 10, 2015 | Dec. 05, 2013 | Dec. 05, 2013 | Oct. 05, 2012 | Nov. 30, 2017 | Dec. 19, 2012 | Dec. 19, 2012 | Nov. 28, 2012 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2015
License, Collaborative and Employment Agreements and Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments for Other Fees |  |  |  |  |  |  |  |  |  |  | $ 4,500,000 |  |  |  |  |  |
Exchange percentage of unregistered common stock |  |  |  |  |  |  |  | 50.00% | 50.00% |  |  |  |  |  |  |  |
Proceeds from (Repurchase of) Equity |  |  |  |  |  |  |  |  | $ 3,000,000 |  |  |  |  |  |  |  |
Options To Be Received Common Stock Shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,000,000 |  |
Milestone Payment upon First Dosing |  |  |  | $ 3,000,000 |  |  |  |  |  |  |  |  |  |  | $ 3,000,000 |  |
Fair Value Of Shares Issued |  |  | $ 285,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Operating Lease, Cost |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 209,000 | $ 201,000 |
Operating Lease, Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 309,000 | 300,000 |
Operating Lease, Weighted Average Discount Rate, Percent |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 9.90% |  |
Research and Development Expense |  |  | $ 198,000 |  |  |  |  |  |  |  |  |  |  |  | $ 5,131,000 | 11,083,000 |
SYN Biomics [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional Number Of Common Stock To Be Issued |  |  | 2,420,000 | 2,420,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 17.00% |  |
Cedarssinai Medical Center [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage Of Common Stock Outstanding |  |  |  |  |  |  |  |  | 11.50% |  |  |  |  |  |  |  |
Payments to Acquire in Process Research and Development |  |  | $ 441,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number Of Common Stock To Be Issued |  |  | 50,000 | 50,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Number Of Common Stock To Be Held By Related Party |  |  | 7,480,000 | 7,480,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Cedarssinai Medical Center [Member] | SYN Biomics [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional Number Of Common Stock To Be Issued |  |  | 2,420,000 | 2,420,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Mark Pimentel M.D [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage Of Common Stock Outstanding |  |  |  |  |  |  |  |  | 8.50% |  |  |  |  |  |  |  |
Licensing Agreements [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual payments due under license agreement |  |  |  |  |  |  |  |  |  |  |  | $ 50,000 |  |  |  |  |
Final payment due under license agreement |  |  |  |  |  |  |  |  |  |  |  | 25,000 |  |  |  |  |
Payments for Other Fees |  |  |  |  |  |  |  | $ 150,000 |  |  |  |  |  |  |  |  |
Stock Issued During Period, Shares, New Issues |  |  |  |  |  |  |  | 9,569 |  |  |  |  |  |  |  |  |
Patents [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments for Other Fees |  |  |  |  |  |  |  | $ 220,000 |  |  |  |  |  |  |  |  |
Steven A. Shallcross [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage | 62.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 450,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intrexon [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock Issued During Period, Shares, Acquisitions |  |  |  |  |  |  |  |  |  | 101,492 |  |  |  |  |  |  |
Shares Issued, Price Per Share |  |  |  |  |  |  |  |  |  | $ 0.001 |  |  |  |  |  |  |
Milestone Payment upon First Dosing |  |  |  |  |  |  | $ 2,000,000 |  |  |  |  |  |  |  | $ 2,000,000 |  |
Prev Abr Llc [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional Cash Payment for License Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 235,000 |  |  |
Unregistered Shares Issued to License Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  | 17,858 |  |  |
Additional Consideration Payable |  |  |  |  |  |  |  |  |  |  |  |  |  | 50% in cash and 50% in our stock |  |  |
Options To Be Received Common Stock Shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 18,724
Phase I Clinical Trials [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone Payment |  |  |  |  |  |  |  |  |  |  |  |  | $ 50,000 |  |  |  |
Phase III Clinical Trials [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone Payment |  |  |  |  |  |  |  |  |  |  |  |  | 100,000 |  |  |  |
NDA Submission In US [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone Payment |  |  |  |  |  |  |  |  |  |  |  |  | 250,000 |  |  |  |
European Medicines Agency Approval [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone Payment |  |  |  |  |  |  |  |  |  |  |  |  | 100,000 |  |  |  |
Regulatory Approval In Asian Country [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone Payment |  |  |  |  |  |  |  |  |  |  |  |  | 100,000 |  |  |  |
PKU ECC [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares, Issued |  |  |  |  |  |  | 26,786 |  |  |  |  |  |  |  |  |  |
Stock Issued |  |  |  |  |  |  | $ 3,000,000 |  |  |  |  |  |  |  |  |  |
Stock Purchase Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Conversion of Stock, Shares Converted |  |  |  |  |  | 38,572 |  |  |  |  |  |  |  |  |  |  |
Conversion of Stock, Shares Issued |  |  |  |  | 38,572 |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Expense |  |  |  | $ 225,000 |  |  |  |  |  |  |  |  |  |  | $ 225,000 | $ 198,000 |
Clinical Trial Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Estimated Research Costs |  | $ 3,200,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
First Year [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research Agreement Fixed Fee |  |  |  |  |  |  |  |  |  |  |  | 303,287 | 303,287 |  |  |  |
Second Year [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research Agreement Fixed Fee |  |  |  |  |  |  |  |  |  |  |  | 316,438 | 316,438 |  |  |  |
Third Year [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research Agreement Fixed Fee |  |  |  |  |  |  |  |  |  |  |  | $ 328,758 | $ 328,758 |  |  |  |

X
- Definition The amount of additional cash payment for license agreement. + References No definition available. + Details
Name: | syn_AdditionalCashPaymentForLicenseAgreement
Namespace Prefix: | syn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Description related to additional consideration payable. + References No definition available. + Details
Name: | syn_AdditionalConsiderationPayable
Namespace Prefix: | syn_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The additional number of common stock to be issued under stock purchase agreement. + References No definition available. + Details
Name: | syn_AdditionalNumberOfCommonStockToBeIssued
Namespace Prefix: | syn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of estimated research services cost provided. + References No definition available. + Details
Name: | syn_EstimatedResearchCosts
Namespace Prefix: | syn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The percentage of common stock outstanding during the period. + References No definition available. + Details
Name: | syn_ExchangePercentageOfUnregisteredCommonStock
Namespace Prefix: | syn_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount represents the fair value of shares issued. + References No definition available. + Details
Name: | syn_FairValueOfSharesIssued
Namespace Prefix: | syn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of annual payments due under the license agreement. + References No definition available. + Details
Name: | syn_LicenseAgreementAnnualPaymentsDue
Namespace Prefix: | syn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of the final payment due under the license agreement. + References No definition available. + Details
Name: | syn_LicenseAgreementFinalPaymentDue
Namespace Prefix: | syn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems
Namespace Prefix: | syn_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition A milestone payment is an authority payment made to a contractor which is linked to the contractor delivering a service or commodity such that, should the agreement be terminated at the point of payment. + References No definition available. + Details
Name: | syn_MilestonePayment
Namespace Prefix: | syn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of milestone payment upon first dosing of a patient in a clinical trail. + References No definition available. + Details
Name: | syn_MilestonePaymentUponFirstDosing
Namespace Prefix: | syn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The additional number of common stock to be held by the related party under stock purchase agreement. + References No definition available. + Details
Name: | syn_NumberOfCommonStockToBeHeldByRelatedParty
Namespace Prefix: | syn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition The number of common stock to be issued under stock purchase agreement. + References No definition available. + Details
Name: | syn_NumberOfCommonStockToBeIssued
Namespace Prefix: | syn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition It Represents options to be received common stock shares reporting period. + References No definition available. + Details
Name: | syn_OptionsToBeReceivedCommonStockShares
Namespace Prefix: | syn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition It represents percentage of common stock outstanding. + References No definition available. + Details
Name: | syn_PercentageOfCommonStockOutstanding
Namespace Prefix: | syn_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of research and development costs incurred for a fixed-price, all payable in quarterly installments. + References No definition available. + Details
Name: | syn_ResearchAgreementFixedFee
Namespace Prefix: | syn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The number of shares issued during the period for license agreement. + References No definition available. + Details
Name: | syn_UnregisteredSharesIssuedToLicenseAgreement
Namespace Prefix: | syn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586 + Details
Name: | us-gaap_ConversionOfStockSharesConverted1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586 + Details
Name: | us-gaap_ConversionOfStockSharesIssued1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Commitment made to pay deferred cash remuneration expressed as a percentage of the individual's base salary. + References No definition available. + Details
Name: | us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity. + References No definition available. + Details
Name: | us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 55 -Paragraph 53 -URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980 + Details
Name: | us-gaap_OperatingLeaseCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 45 -Paragraph 5 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (g)(1) -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980 + Details
Name: | us-gaap_OperatingLeasePayments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Weighted average discount rate for operating lease calculated at point in time. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (g)(4) -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 55 -Paragraph 53 -URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971 + Details
Name: | us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of cash outflow for fees classified as other. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (g) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585 + Details
Name: | us-gaap_PaymentsForFees
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The net cash inflow or outflow resulting from the entity's share transaction. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690 + Details
Name: | us-gaap_ProceedsFromRepurchaseOfEquity
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Gross number of share options (or share units) granted during the period. + References No definition available. + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 + Details
Name: | us-gaap_SharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Per share or per unit amount of equity securities issued. + References No definition available. + Details
Name: | us-gaap_SharesIssuedPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition The fair value of stock issued in noncash financing activities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586 + Details
Name: | us-gaap_StockIssued1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of shares of stock issued during the period pursuant to acquisitions. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesAcquisitions
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_OwnershipAxis=syn_SYNBiomicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_CedarssinaiMedicalCenterMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_MarkPimentelM.dMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_TitleOfIndividualAxis=syn_StevenAShallcrossMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=syn_IntrexonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=syn_PrevAbrLlcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=syn_PhaseIClinicalTrialsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=syn_PhaseIiiClinicalTrialsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=syn_NdaSubmissionInUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=syn_EuropeanMedicinesAgencyApprovalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=syn_RegulatoryApprovalInAsianCountryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=syn_ChannelCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=syn_StockPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=syn_ClinicalTrialAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | syn_QuarterlyInstallmentsPaymentPeriodAxis=syn_FirstYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | syn_QuarterlyInstallmentsPaymentPeriodAxis=syn_SecondYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | syn_QuarterlyInstallmentsPaymentPeriodAxis=syn_ThirdYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |